A phase II study of nivolumab (anti–PD-1 antibody) monotherapy found a 15% overall response rate (ORR) in 20 patients with platinum-resistant disease, while another combination therapy with nivolumab and bevacizumab show a 40% ORR in 38 patients with relapsed ovarian cancer in platinum-sensitive patients and 16.7% in platinum-resistant patients [7, 13]. This evidence concerns the gene PDCD1 and ovarian cancer.